Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $200.00.
Michael Ryskin has given his Buy rating due to a combination of factors including Zoetis’s strong financial performance and growth potential. The company reported a solid first quarter with a 9% year-over-year organic sales growth and an adjusted earnings per share that exceeded expectations. Additionally, Zoetis raised its full-year 2025 sales and earnings guidance, reflecting confidence in its operational strategy and favorable foreign exchange impacts.
Despite some concerns regarding the performance of Librela in the US market, Ryskin believes that Zoetis’s overall growth prospects remain robust. The company is effectively countering competitive pressures with strong performances in other products like Simparica Trio and Derm. Furthermore, targeted reinvestments in marketing channels are expected to boost future growth. Ryskin maintains a price objective of $200, viewing Zoetis as a leader in an industry with enduring growth drivers.
In another report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $180.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year.